Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-853.81%
operating margin TTM
-1215.15%
revenue TTM
104.28 Thousand
revenue per share TTM
0.03$
valuation ratios | |
|---|---|
| pe ratio | -0.33 |
| peg ratio | 0.02 |
| price to book ratio | 0.77 |
| price to sales ratio | 4.27 |
| enterprise value multiple | -0.71 |
| price fair value | 0.77 |
profitability ratios | |
|---|---|
| gross profit margin | -314.7% |
| operating profit margin | -1215.15% |
| pretax profit margin | -839.47% |
| net profit margin | -853.81% |
| return on assets | -131.29% |
| return on equity | -408.94% |
| return on capital employed | -330.53% |
liquidity ratio | |
|---|---|
| current ratio | 2.15 |
| quick ratio | 2.15 |
| cash ratio | 1.56 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 220.37 |
| days of payables outstanding | 130.70 |
| cash conversion cycle | 89.67 |
| receivables turnover | 1.66 |
| payables turnover | 2.79 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.02 |
| debt equity ratio | 0.03 |
| long term debt to capitalization | 0.01 |
| total debt to capitalization | 0.03 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -75.94 |
cash flow ratios | |
|---|---|
| free cash flow per share | -4.17 |
| cash per share | 2.40 |
| operating cash flow per share | -4.17 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -75.94 |
| short term coverage ratios | -96.49 |
| capital expenditure coverage ratio | -702.19 |
Frequently Asked Questions
When was the last time Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) reported earnings?
Sonnet BioTherapeutics Holdings, Inc. (SONN) published its most recent earnings results on 13-02-2025.
What is Sonnet BioTherapeutics Holdings, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN)'s trailing twelve months ROE is -408.94%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Sonnet BioTherapeutics Holdings, Inc. (SONN) currently has a ROA of -131.29%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did SONN's net profit margin stand at?
SONN reported a profit margin of -853.81% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is SONN's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 2.15 in the most recent quarter. The quick ratio stood at 2.15, with a Debt/Eq ratio of 0.03.